Tunariu, Nina

Integrative Clinical Genomics of Advanced Prostate Cancer

Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell

Prostate Cancer Treatment and ResearchCancer Genomics and Diagnostics

Cited by 3,645

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine

PARP inhibition in cancer therapyProstate Cancer Treatment and Research

Cited by 2,185

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science

Cancer Cells and MetastasisColorectal Cancer Treatments and Studies

Cited by 2,096

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer

Paschalis, A., Sheehan, B., Riisnaes, R., Rodrigues, D. N., Gurel, B., Bertan, C., Ferreira, A., Lambros, M. B. K., Seed, G., Yuan, W., et al. (2019) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 455

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

Ferraldeschi, R., Nava Rodrigues, D., Riisnaes, R., Miranda, S., Figueiredo, I., Rescigno, P., Ravi, P., Pezaro, C., Omlin, A., Lorente, D., et al. (2015) · European Urology

Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 268

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

Boysen, G., Rodrigues, D. N., Rescigno, P., Seed, G., Dolling, D., Riisnaes, R., Crespo, M., Zafeiriou, Z., Sumanasuriya, S., Bianchini, D., et al. (2018) · Clinical Cancer Research

Prostate Cancer Treatment and ResearchChromatin Remodeling and Cancer

Cited by 145

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 78

HER3 Is an Actionable Target in Advanced Prostate Cancer

Gil, V., Miranda, S., Riisnaes, R., Gurel, B., D’Ambrosio, M., Vasciaveo, A., Crespo, M., Ferreira, A., Brina, D., Troiani, M., et al. (2021) · Cancer Research

Prostate Cancer Treatment and ResearchHER2/EGFR in Cancer Research

Cited by 68

725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Banerjee, S., Grochot, R., Shinde, R., Lima, J., Krebs, M., Rahman, R., Little, M., Tunariu, N., Curcean, A., Badham, H., et al. (2021) · Annals of Oncology

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 17

Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., et al. (2021) · Cancer Research

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 10

3381: Primary endpoint analysis of TRAP, first prospective Phase II trial of SBRT to oligoprogressive disease prostate cancer (NCT03644303)

Patel, P., Dreibe, S., Attard, G., Cole, A. J., Frew, J., Guevara, J., Mullassery, V., Murray, J., Parker, C., Palaniappan, N., et al. (2024) · Radiotherapy and Oncology

Prostate Cancer Diagnosis and TreatmentAdvanced Radiotherapy Techniques

Cited by 4